Abstract: A multilayered cell culture apparatus for the culturing of cells is disclosed. The cell culture apparatus is defined as an integral structure having a plurality of cell culture chambers in combination with tracheal space(s). The body of the apparatus has imparted therein gas permeable membranes in combination with tracheal spaces that will allow the free flow of gases between the cell culture chambers and the external environment. The flask body also includes an aperture that will allow access to the cell growth chambers by means of a needle or cannula. The size of the apparatus, and location of an optional neck and cap section, allows for its manipulation by standard automated assay equipment, further making the apparatus ideal for high throughput applications.
Type:
Grant
Filed:
May 29, 2013
Date of Patent:
September 30, 2014
Assignee:
Corning Incorporated
Inventors:
Gregory Roger Martin, Allison Jean Tanner
Abstract: The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.
Type:
Grant
Filed:
March 3, 2011
Date of Patent:
September 30, 2014
Assignees:
University of Pittsburgh—of the Commonwealth System of Higher Education, The University of Chicago, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas—D.F.
Inventors:
Naftali Kaminski, Kevin F. Gibson, Bernadette R. Gochuico, Thomas J. Richards, Ivan Rosas, Kazuhisa Konishi, Moises Selman, Jose David Herazo-Maya, Imre Noth
Abstract: Compositions and methods of treatments of cells are provided for altering the phenotype of a cell by administering an oligonucleotide complex to the cell, the complex having two strands and chemical modifications.
Type:
Grant
Filed:
March 13, 2012
Date of Patent:
September 23, 2014
Assignee:
The General Hospital Corporation
Inventors:
David R. Tabatadze, Paul C. Zamecnik, Malay K. Raychowdhury, Horacio F. Cantiello
Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.
Abstract: The invention provides methods, materials and systems of regulating association between proteins of interest using light. In an aspect, the invention takes advantage of the ability of phytochromes to change conformation upon exposure to appropriate light conditions, and to bind in a conformation-dependent manner to cognate proteins called phytochrome-interacting factors. The invention comprises a method of regulating interaction between a first protein of interest and second protein within a cell by light. Such a method optionally comprises providing in the cell (1) a first protein construct which comprises the first protein, a phytochrome domain (PHD), and (2) providing in the cell a second protein construct which comprises the second protein and a phytochrome domain-interacting peptide (PIP) that can bind selectively to the Pfr state, but not to the Pr state, of the phytochrome domain.
Type:
Grant
Filed:
May 26, 2009
Date of Patent:
September 9, 2014
Assignee:
The Regents of the University of California
Inventors:
Christopher A. Voigt, Anselm Levskaya, Wendell Lim
Abstract: The invention provides eukaryotic unicellular algae engineered to express a nucleosome alteration protein fused to a protein with affinity to the DNA binding site acting in coordination. An example is a LexA-p300 fusion protein, where the p300 is derived from Chlamydomonas. The LexA binding domain guides the p300 to the binding site and the p300 loosens the nucleosome structure by acetylating histones within proximity of the transgene, thus remodeling the local chromatin structure to allow for high-level expression.
Abstract: The present invention relates to a method for increasing the expression of a protein in cells, preferably in eukaryotic cells, by reducing the number of RNase L cleavage sites in the coding and/or non-coding region of the nucleic acid sequence of said protein. Furthermore, it relates to nucleic acid sequences exhibiting a reduced number of RNase L cleavage sites as well as to the proteins translated from such sequences.
Type:
Grant
Filed:
January 19, 2010
Date of Patent:
July 29, 2014
Assignees:
King Faisal Specialist Hospital & Research Centre, Terramark Markencreation GmbH
Abstract: The present invention generally relates to a method for seeding cells on to a support. In particular, the method relates to a method for seeding cells onto a porous hydrophobic support. The method utilizes centrifugal forces to uniformly guide cell seeding into the support with no loss in viability.
Abstract: The present invention relates to methods of generating an ex vivo tissue-like system in a bioreactor system capable of supporting continuous production of, and output of cells and tissues and an ex vivo tissue system made therefrom.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
July 15, 2014
Assignee:
Aastrom Biosciences, Inc.
Inventors:
Lee Noll, Brian Hampson, Kristin Goltry, Samantha Snabes
Abstract: The invention relates to aptamer-regulated, ligand-responsive nucleic acids, or “ampliSwitches,” and uses thereof. Particular embodiments include a ligand-responsive nucleic acid that comprises a primer sequence domain and an aptamer domain that is responsive to a ligand.
Abstract: The present invention concerns the methods and compositions involving nucleic acids with long repeat sequences. In some embodiments of the invention, there are methods for generating such a nucleic acid, and in other methods, there are methods for using such a nucleic acid to screen for candidate therapeutic compounds. Furthermore the present invention relates to methods of screening for Notch inhibitors and other substances that may be used to treat muscle loss and wasting.
Type:
Grant
Filed:
March 14, 2012
Date of Patent:
July 8, 2014
Assignee:
The Board of Regents of the University of Texas System
Abstract: In one embodiment of the invention, there is provided a method of selecting a surface chemistry for culturing a given cell line, including the steps of: (i) providing a first substrate having a plasma polymerized surface with first and second regions, said first region having a first concentration of carboxylic acid groups on said plasma polymerized surface and said second region having a second concentration of carboxylic acid groups on said plasma polymerized surface, wherein said first and second concentrations are different; (ii) culturing cells from said cell line on said plasma polymerized surface in each said region; (iii) observing activity of said cultured cells in each said region, said activity selected from the group consisting of alkaline phosphatase activity of the cultured cells, cell growth of the cultured cells, attachment of the cultured cells, and cell spreading of the cultured cells; and iv) selecting, based on a particular observed activity, a secondary substrate for culturing said cells
Type:
Grant
Filed:
July 29, 2013
Date of Patent:
June 10, 2014
Assignee:
Corning Incorporated
Inventors:
Robert Short, Patricia Murray, Kristina Parry
Abstract: The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
June 3, 2014
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Inventors:
Domenico Coppola, Dung-Tsa Chen, Steven Brem
Abstract: Methods of assessing genomic instability in breast cancer tissue by measuring the expression level of genes CDKN2A, SCYA18, STK15, NXF1, cDNA Dkfzp762M127, p28 KIAA0882, MYB, Human clone 23948, RERG, HNF3A, and ACADSB or a nucleic acid sequence comprising about 90% or greater sequence identity to SEQ ID NO: 21 in breast cancer tissue, an array suitable for use in such methods, and related methods and compositions.
Type:
Grant
Filed:
September 15, 2009
Date of Patent:
June 3, 2014
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, West Virginia University Research Corporation
Inventors:
Karl Thomas Ried, Jens Habermann, Nancy Lan Guo, Gert Auer
Abstract: The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient.
Type:
Grant
Filed:
July 2, 2009
Date of Patent:
May 20, 2014
Assignee:
Assistance Publique-Hopitaux de Paris
Inventors:
Philippe Broet, Sophie Camilleri-Broet, Lance Miller, Patrick Tan
Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.
Type:
Grant
Filed:
October 5, 2012
Date of Patent:
May 20, 2014
Assignee:
Corning Incorporated
Inventors:
Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
Abstract: Genome-wide association studies (GWAS) was recently used to identify SNPs in a genomic region on chromosome 4 that associate with serum urate levels and gout. The present disclosure shows that human ATP-binding cassette, subfamily G, 2 (ABCG2), encoded by the ABCG2 gene contained in this region, is a hitherto unknown urate efflux transporter. The present disclosure further shows that native ABCG2 is located in the brush border membrane of kidney proximal tubule cells, where it mediates renal urate secretion. Introduction of the mutation Q141K encoded by the common SNP rs2231142 by site-directed mutagenesis resulted in reduced urate transport rates compared to wild-type ABCG2. Data from a population-based study of 14,783 individuals support rs2231142 as the causal variant in the region and show highly significant associations with urate levels and gout.
Type:
Grant
Filed:
March 11, 2010
Date of Patent:
May 13, 2014
Assignee:
The Johns Hopkins University
Inventors:
Michael Kottgen, Josef Coresh, William Guggino, Anna Kottgen, Owen Woodward
Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
Type:
Grant
Filed:
June 14, 2012
Date of Patent:
April 29, 2014
Assignee:
BioAtla, LLC
Inventors:
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.